WOBE437

WOBE437 is a potent endocannabinoid uptake inhibitor with IC50 values of 10 and 283 nM for arachidonoyl ethanolamide (AEA, Cay-90050) and 2-arachidonoyl glycerol (2-AG, Cay-62160) uptake, respectively, in U937 cells. It is greater than 1,000-fold selective for endocannabinoid transporters over fatty acid amide hydrolase (FAAH, Cay-10010183) and the 2-AG hydrolyzing enzymes MAGL, ABHD6, and ABHD12. WOBE437 inhibits AEA uptake in FAAH-deficient HMC-1 human mast cells and Neuro2a mouse neuroblastoma cells (IC50s = 137 and 55 nM, respectively) and reduces AEA uptake by 50% in rat cortical neurons when used at a concentration of 1 µM. It also reduces 2-AG uptake by 40% in Neuro2a cells at a concentration of 5 µM. In vivo, WOBE437 increases AEA and 2-AG levels by 1.5-fold in mouse brain but not peripheral tissues after intraperitoneal administration of a 10 mg/kg dose for seven days. WOBE437 (10 mg/kg) also induces a typical tetrad of hypothermia, catalepsy, analgesia, and hypomotility in mice, indicating it also acts as an indirect cannabinoid (CB) receptor 1 agonist.Formal Name: (2E,4E)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2,4-dodecadienamide. CAS Number: 2108100-73-6. Molecular Formula: C22H33NO3. Formula Weight: 359.5. Purity: >97%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 2.5 mg/ml, DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml, DMSO: 1 mg/ml. lambdamax: 254 nm. SMILES: COC1=CC=C(CCNC(/C=C/C=C/CCCCCCC)=O)C=C1OC. InChi Code: InChI=1S/C22H33NO3/c1-4-5-6-7-8-9-10-11-12-13-22(24)23-17-16-19-14-15-20(25-2)21(18-19)26-3/h10-15,18H,4-9,16-17H2,1-3H3,(H,23,24)/b11-10+,13-12+. InChi Key: LAHLFCSEHHJQRN-AQASXUMVSA-N.